Clinical variables impacting on the estimation of utilities in chronic obstructive pulmonary disease
- PMID: 25733826
- PMCID: PMC4337593
- DOI: 10.2147/COPD.S76397
Clinical variables impacting on the estimation of utilities in chronic obstructive pulmonary disease
Abstract
Purpose: Health utilities are widely used in health economics as a measurement of an individual's preference and show the value placed on different health states over a specific period. Thus, health utilities are used as a measure of the benefits of health interventions in terms of quality-adjusted life years. This study aimed to determine the demographic and clinical variables significantly associated with health utilities for chronic obstructive pulmonary disease (COPD) patients.
Patients and methods: This was a multicenter, observational, cross-sectional study conducted between October 2012 and April 2013. Patients were aged ≥40 years, with spirometrically confirmed COPD. Utility values were derived from the preference-based generic questionnaire EQ-5D-3L applying weighted Spanish societal preferences. Demographic and clinical variables associated with utilities were assessed by univariate and multivariate linear regression models.
Results: Three hundred and forty-six patients were included, of whom 85.5% were male. The mean age was 67.9 (standard deviation [SD] =9.7) years and the mean forced expiratory volume in 1 second (%) was 46.2% (SD =15.5%); 80.3% were former smokers, and the mean smoking history was 54.2 (SD =33.2) pack-years. Median utilities (interquartile range) were 0.81 (0.26) with a mean value of 0.73 (SD =0.29); 22% of patients had a utility value of 1 (ceiling effect) and 3.2% had a utility value lower than 0. The factors associated with utilities in the multivariate analysis were sex (beta =-0.084, 95% confidence interval [CI]: -0.154; -0.013 for females), number of exacerbations the previous year (-0.027, 95% CI: -0.044; -0.010), and modified Medical Research Council Dyspnea Scale (mMRC) score (-0.123 [95% CI: -0.185; -0.061], -0.231 [95% CI: -0.301; -0.161], and -0.559 [95% CI: -0.660; -0.458] for mMRC scores 2, 3, and 4 versus 1), all P<0.05.
Conclusion: Multivariate analysis showed that female sex, frequent exacerbations, and an increased level of dyspnea were the main factors associated with reduced utility values in patients with COPD.
Keywords: COPD; health utility; health-related quality of life; multivariate linear regression.
Figures
Similar articles
-
Modified Medical Research Council scale vs Baseline Dyspnea Index to evaluate dyspnea in chronic obstructive pulmonary disease.Int J Chron Obstruct Pulmon Dis. 2015 Aug 18;10:1663-72. doi: 10.2147/COPD.S82408. eCollection 2015. Int J Chron Obstruct Pulmon Dis. 2015. PMID: 26316740 Free PMC article.
-
Factors associated with inadequate diagnosis of COPD: On-Sint cohort analysis.Int J Chron Obstruct Pulmon Dis. 2015 May 18;10:961-7. doi: 10.2147/COPD.S79547. eCollection 2015. Int J Chron Obstruct Pulmon Dis. 2015. PMID: 26028969 Free PMC article.
-
Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?Chest. 2006 Oct;130(4):1117-28. doi: 10.1378/chest.130.4.1117. Chest. 2006. PMID: 17035446 Clinical Trial.
-
Do Model-Based Studies in Chronic Obstructive Pulmonary Disease Measure Correct Values of Utility? A Meta-Analysis.Value Health. 2016 Jun;19(4):363-73. doi: 10.1016/j.jval.2016.01.012. Epub 2016 Mar 24. Value Health. 2016. PMID: 27325328 Review.
-
Patient reported outcome measures in chronic obstructive pulmonary disease: Which to use?Expert Rev Respir Med. 2016;10(3):351-62. doi: 10.1586/17476348.2016.1146595. Epub 2016 Feb 16. Expert Rev Respir Med. 2016. PMID: 26808786 Review.
Cited by
-
Relative impact of COPD and comorbidities on generic health-related quality of life: a pooled analysis of the COSYCONET patient cohort and control subjects from the KORA and SHIP studies.Respir Res. 2016 Jul 12;17(1):81. doi: 10.1186/s12931-016-0401-0. Respir Res. 2016. PMID: 27405652 Free PMC article.
-
Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients.Int J Chron Obstruct Pulmon Dis. 2016 Jan 18;11:123-32. doi: 10.2147/COPD.S94006. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 26848262 Free PMC article.
-
Burden of Disease Among Exacerbating Patients with COPD Treated with Triple Therapy in Spain.Int J Chron Obstruct Pulmon Dis. 2021 Jul 21;16:2149-2161. doi: 10.2147/COPD.S310319. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 34321874 Free PMC article.
-
The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort.Int J Chron Obstruct Pulmon Dis. 2017 Dec 4;12:3437-3448. doi: 10.2147/COPD.S141852. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 29270005 Free PMC article.
-
Residual respiratory disability after successful treatment of pulmonary tuberculosis: a systematic review and meta-analysis.EClinicalMedicine. 2023 May 8;59:101979. doi: 10.1016/j.eclinm.2023.101979. eCollection 2023 May. EClinicalMedicine. 2023. PMID: 37205923 Free PMC article.
References
-
- López-Campos JL, Ruiz-Ramos M, Soriano JB. Mortality trends in chronic obstructive pulmonary disease in Europe, 1994–2010: a joinpoint regression analysis. Lancet Respir Med. 2014;2(1):54–62. - PubMed
-
- Miravitlles M, Soriano JB, García-Río F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily activities. Thorax. 2009;64(10):863–868. - PubMed
-
- Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med. 1997;127(12):1072–1079. - PubMed
-
- Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5(1):1–30. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous